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Mesenchymal stem cell/stromal cells (MSCs) can differentiate into a variety 
of cell types, including osteocytes, adipocytes and chondrocytes. MSCs are pres-
ent in the multiple types of adult tissue, such as bone marrow, adipose tissue, and 
various neonatal birth-associated tissues. Given their self-renewal and differentia-
tion potential, immunomodulatory and paracrine properties, and lacking major 
histocompatibility complex (MHC) class II molecules, MSCs have attracted much 
attention for stem cell-based translational medicine research. Due to a very low 
frequency in different types of tissue, MSCs can be isolated and expanded in vitro to 
derive sufficient cell numbers prior to the clinical applications. In this chapter, the 
methodology to obtain primary bone marrow-derived MSCs as well as their in vitro 
culture expansion will be described. To assess the functional properties, differentia-
tion assays, including osteogenesis, chondrogenesis and adipogenesis, 3-D culture 
of MSCs and co-culture of MSCs and tumor cells are also provided. Finally, the 
long-term culture associated alterations of MSCs, such as replicative senescence and 
spontaneous transformation, will be discussed for better understanding of the use 
of MSCs at the early stages for safe and effective cell-based therapy.
Keywords: Mesenchymal stem cell/stromal cells, primary culture, co-culture,  
3-D culture, replicative senescence, spontaneous transformation
1. Introduction
Mesenchymal stem/stromal cells (MSCs), a multipotent stem/progenitor cell 
type, were initially described in bone marrow by Friedenstein et al. as rapid adher-
ence to tissue culture vessels and the discrete “fibroblast” colonies approximately 
50 years ago [1, 2]. Julius Cohnheim, a German-Jewish pathologist, firstly proposed 
that a fibroblast-like cell population for nonhematopoietic cells in bone marrow 
were involved in wound repair over 150 years ago [3]. In the late 1980s, Caplan 
firstly coined the name “mesenchymal stem cell (MSC)” [4]. Since then, MSCs 
have gained much attention over the last three decades. Many laboratories focus-
ing on MSCs have developed diverse methods to isolate and expand MSCs from a 
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variety of tissues. While the assessment of characteristics of MSCs is necessitated 
in different platforms/laboratories, most researchers come to acknowledge the lack 
of a universally accepted criteria to define MSCs. To address this question of cell 
equivalence, the Mesenchymal and Tissue Stem Cell Committee of the International 
Society for Cellular Therapy (ISCT) proposes three minimal criteria to define MSCs 
[5]: property of MSC plastic adherence, the expression of specific cellular surface 
antigen, and capacity for trilineage mesenchymal differentiation (osteogenesis, 
chondrogenesis and adipogenesis).
Human MSCs from different tissues have the varied phenotypic features, the 
morphologic inconsistency, and heterogeneous functional behavior [6–8]. Indeed, 
the properties of stem cell have not been well established yet. Due to the unknown 
in vivo multipotent properties of MSCs, the issue of MSC nomenclature remains 
actively controversial. In 2019, ISCT MSC committee issued a position statement 
on nomenclature of MSCs clarifying the functional definition to emphasize the 
functional distinction of mesenchymal stem versus stromal cells [9].
MSCs have been considered as a promising therapeutic tool in tissue engineering 
and regenerative medicine. MSCs are well known to be present in almost every type 
of adult tissues, such as bone marrow [10–12], adipose tissue [10, 13, 14], lung [11, 
15], synovial tissue [16, 17], dental pulp and periodontal ligament [18]. Notably, it has 
become apparent that MSCs are identified in the various human embryonic tissues, 
such as fetal bone marrow [19], fetal liver [20], aorta gonad-mesonephros and yolk 
sac [21], as well as multiple neonatal birth-associated tissues, such as placenta [10, 
22, 23], amniotic and chorionic membrane [23, 24], umbilical cord tissue [10, 23–25], 
and umbilical cord blood [26, 27]. Therefore, different platforms/laboratories may 
use different type of tissue sources and methodologies for isolation and expansion of 
MSCs. This chapter firstly outlines protocols for standardized isolation and expan-
sion of human bone marrow-derived MSCs (BM-MSCs), a major source of human 
MSCs, as well as BM-MSCs’ characteristics, cryopreservation and thawing. Protocols 
for the preparation of MSCs derived from the other tissue types are similar to that 
of BM-MSCs, except tissue sample processing differentially. Human BM-MSCs are 
estimated at a very low frequency at approximately 0.001–0.01% of total nucleated 
cells [28, 29], and, therefore, human BM-MSCs are likely to be kind of difficult to 
isolate and harvest. This chapter will then focuses on optimal functional assays and 
application on the basis of our previous studies, which would be useful for researchers 
working with MSCs in basic research and translational and clinical applications, such 
as osteogenesis, chondrogenesis, adipogenesis, colony forming unit-fibroblast (CFU-
F) assay, 3-D cellular co-culture, MSC homing and migration. Last but not least, the 
long-term culture associated alterations of MSCs’ properties will be also discussed in 
this chapter.
2.  Isolation, culture expansion, phenotypic analysis, freezing and 
thawing of human BM-MSCs
2.1 Materials
1. Growth medium (pH 7.1–7.5): Dulbecco’s modified Eagle’s medium (DMEM)-
low glucose (Sigma-Aldrich, St Louis, MO), 10% fetal bovine serum (FBS, heat-
inactivated) (Atlanta Biologicals, Lawrenceville, GA), 0.37 g% sodium bicar-
bonate, and 1% penicillin–streptomycin. Adjust growth medium to pH 7.1–7.5.
2. Ficoll-Paque (Density gradient medium) (Stem Cell Technologies, Cam-
bridge, MA).
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3. 1 × Phosphate buffered saline (PBS), pH 7.2.
4. 1 × PBS + 2% + 1 mM ethylenediaminetetraacetic acid (EDTA).
5. Trypan blue, 0.4%.
6. Freezing medium: 90% FBS and 10% (v/v) dimethyl sulphoxide (DMSO).
7. Trypsin–EDTA solution 0.25% (Sigma, St. Louis, MO).
8. RosetteSep™ Human Mesenchymal Stem Cell Enrichment Cocktail (Stem Cell 
Technologies, Cambridge, MA).
9. Nalgene® Cryo 1°C Freezing Container.
10. Cryogenic storage vials.
11. Suitable box for storage in liquid nitrogen.
12. Tissue culture ware: T25 flasks, T75 flasks, 100-mm tissue culture dishes, 
6-well plates.
13. Hemocytometer.
14. Water bath at 37°C.
15. Biological safety cabinet class II.
16. Bench centrifuge with swinging bucket rotor.
17. Inverted phase microscope.
18. Sterile conical centrifuge tubes (15 and 50 mL).
19. Sterile cell culture plastic pipettes (2, 5, 10, 25 mL).
20. Automatic pipettor.
21. 1.5 mL eppendorf tubes.
2.2 Isolation and culture expansion of human BM-MSCs
1. Make sure BM sample, 1 × PBS + 2% FBS + 1 mM EDTA, Ficoll-Paque and 
centrifuge are all at room temperature.
2. Spray the sample tube with 70% ethanol and conduct the isolation of BM-
MSCs in the Biological Safety cabinet.
3. For 10 mL size of BM, divide BM sample into two 50 mL conical tubes at 
room temperature. Add 50 μl RosetteSep Human Mesenchymal Stem Cell En-
richment Cocktail per mL of bone marrow and mix well.
4. Incubate for 20 minutes at room temperature.
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5. Dilute sample with about same volume of 1 × PBS + 2% FBS + 1 mM EDTA 
solution; mix gently.
6. Prepare two 50 mL conical tubes with 10 mL Ficoll-Paque each tube. Layer the 
diluted sample on top of Ficoll-Paque. Be careful to minimize mixing of Ficoll-
Paque and sample. Tilt the tube to 45 degree angle and slowly add the sample 
drop by drop to form a layer on top.
7. Centrifuge at 1200 × g for 10 minutes at room temperature in a swinging 
bucket rotor and set the centrifuge to brake on.
8. Remove the enriched cells from the Ficoll-Paque. Collect the interphase con-
taining the mononuclear cells. Be sure not to touch the red pellet at the bottom. 
It is advisable to remove some of the Ficoll-Paque and a bit of upper plasma 
layer in order to endure complete recovery of the desired cells.
9. Wash enriched cells with the 5× volume of 1 × PBS + 2% FBS + 1 mM EDTA 
solution. Spin 300 × g for 10 minutes.
10. Carefully discard the supernatant and resuspend cells in 1 mL of MSC growth 
medium per tube. Perform a viable cell count with a hemocytometer using 
Trypan blue.
11. Seed cells into one T-75 flask finally for 10 mL size marrow (a final cell con-
centration of 0.5–1.5 × 106 cells/cm2). 12 mL of MSC growth medium is 
supplemented.
12. Put the flask in incubator at 37°C with 5% humidified CO2 for 48 hours to al-
low cells to attach.
13. After 48 hours, observe with phase contrast microscopy and then remove 
growth medium and non-adherent cells.
14. Wash cells twice with pre-warmed medium and add 13 mL of fresh MSC 
growth medium. Return the flask to the incubator.
15. Change growth medium every 3 days and observe the cellular colony forming.
16. CFU-F become in the next 3–5 days. Continue to culture until the cells reach 
80% confluence in the 2 weeks.
17. Remove the medium and wash with PBS 2–3 times.
18. Add 3–4 mL pre-warmed trypsin–EDTA solution to cover cells in the flask. 
Return the flask to the incubator for 5 minutes.
19. Check with phase contrast microscopy. When most cells become detached, 
gently tap the side of the flask.
20. Add 5 mL growth medium to the flask to stop Trypsin–EDTA action. Resus-
pend cells by pipetting and transfer the entire cell suspension into a 15 mL 
conical tube.
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21. Centrifuge at 400 × g for 5 minutes.
22. Remove the supernatant and resuspend the cells in 2–3 mL pre-warmed PBS. 
Centrifuge at 400 × g for 5 minutes.
23. Repeat step 22.
24. Harvest cells. This culture is considered as passage 0.
25. Count cells and reseed cells at an optimum density of 5000 cells/cm2 in the ap-
propriate tissue culture ware.
26. After 24 hours, remove the growth medium and wash the cells attached to the 
plate once with PBS.
27. Add the appropriate volume of fresh culture medium and incubate the cells for 
2–3 days.
28. When the culture reaches 80–90% confluence, remove the culture medium 
and wash with PBS 2–3 times.
29. For trypsinization, add an appropriate volume of pre-warmed trypsin–EDTA 
solution to cover the entire cellular surface. Return the flask to the incubator 
for 5 minutes.
30. Observe under a phase contrast microscope. When most cells become de-
tached, gently tap the side of the flask.
31. Add the appropriate volume of growth medium to stop Trypsin–EDTA action. 
Mix and collect the mixture of the entire cell suspension into a 15 mL conical tube.
32. Centrifuge at 400 × g for 5 minutes at room temperature.
33. Remove the supernatant without disturbing the cell pellet and resuspend the 
cells with an appropriate volume of pre-warmed PBS.
34. Wash and centrifuge at 400 × g for 5 minutes again.
35. Harvest cells. This culture is passage 1. MSCs at passage 1 can be frozen in liq-
uid nitrogen (see the next) or continue to serially passage.
2.3 Characteristics of the expanded human BM-MSCs
The following antibodies are used in flow cytometry analysis of MSC char-
acterization, CD29-PE, CD34-PE, CD44-PE, CD73-PE, CD90-PE, CD45-FITC, 
CD147-FITC, HLA DR-FITC, IgG1-PE, and IgG1-FITC (BD Biosciences). IgG1 
immunoglobulin is used as isotype negative controls and passage 3 MSCs are charac-
terized using PE or FITC conjugated antibodies against the cellular surface markers.
1. Remove the growth medium and wash cells with pre-warmed PBS twice.
2. Add the pre-warmed trypsin–EDTA solution to the flask. Return the flask to 
the incubator for 5 minutes.
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3. When most cells become detached, gently tap the side of the flask.
4. Add growth medium to the flask. Mix and transfer the entire cell suspension 
into a 15 mL conical tube.
5. Centrifuge at 400 × g for 5 minutes.
6. Remove the supernatant and resuspend the cells in the pre-warmed PBS.
7. Centrifuge at 400 × g for 5 minutes.
8. Carefully discard the supernatant and resuspend cells with pre-warmed PBS.
9. Centrifuge at 400 × g for 5 minutes.
10. Harvest cells.
11. Count cells and make it a single cell suspension at concentration of 1x106 cells/
mL in PBS.
12. Add 250 μL cellular suspension to the appropriate number of FACS tubes.
13. Add antibodies to the FACS tubes – 10 μL per antibody per tube.
14. Incubate the FACS tubes for 20–25 minutes at room temperature on a shaker to 
prevent aggregation.
15. Then spin down FACS tubes at 150 rpm for 5 minutes.
16. Wash twice with PBS.
17. Add 2 mL MSC growth media.
18. Centrifuge the tubes at 150 rpm for 5 minutes.
19. Pipette off the supernatant.
20. Add 250 μL MSC growth media.
21. Run samples through the FACS machine.
2.4 Freezing of BM-MSCs
Of note, perform all following steps under sterile conditions.
1. Place freezing medium on ice.
2. Harvest the cultivated MSCs, as described above (steps 1–10 in Section 2.3).
3. Resuspend MSCs in freezing medium at a concentration of 5–10 × 105 cells/mL.
4. Transfer cells into appropriate cryogenic storage vials or tubes and close 
the lid.
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5. Place the vials in the pre-cooled Cryo 1°C Freezing Container quickly and store 
at −80°C directly.
6. After 24 hours, transfer the cryogenic storage vials to the suitable boxes to 
liquid nitrogen for long-term storage.
2.5 Thawing of BM-MSCs
Perform all following steps under sterile conditions.
1. Place the frozen vial of MSCs rapidly into a 37°C water bath.
2. Gently swirl the cryovial until the ice in the vial has melted.
3. After thawing, transfer the entire content of the cryovial into a sterile 15 mL 
conical tube containing 5 mL of pre-warmed PBS.
4. Gently swirl and centrifuge at 400 × g for 5 minutes.
5. Aspirate supernatant completely.
6. Wash again.
7. Count and reseed cells at a density of 5000 cells/cm2 in the appropriate tissue 
culture ware.
3. Functional analysis of expanded human MSCs
3.1 In vitro osteogenesis of human BM-MSCs
Osteogenic medium: MSC growth medium supplemented with 50 μM ascorbic 
acid phosphate (AsAP) (Wako Chemicals USA, Richmond, VA), 0.1 μM dexameth-
asone (Sigma-Aldrich, St Louis, MO), and 10 mM β-glycerol phosphate (Sigma-
Aldrich, St Louis, MO).
Several osteogenic markers, such as alkaline phosphatase (ALP), leptin recep-
tor, and cathepsin K, are used as the indicator of early osteogenesis [28], calcium 
deposition as the indicator of late-stage osteogenesis [28, 29]. ALP activity and 
calcium deposition are exemplified to assess osteogenic differentiation of human 
MSCs from passage 4 (Figure 1).
3.1.1 Colorimetric quantitative ALP activity
1. Collect cells from passage 4.
2. Prepare cellular suspension in growth medium.
3. Plate cellular suspension in 6-well plates at 1 × 105 cells/well in triplicate.
4. After 24 hours, remove the growth medium and wash cells with osteogenic 
medium once.
5. Add 2 mL osteogenic medium in each well.
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6. Culture cells in incubator at 37°C with 5% humidified CO2.
7. Change osteogenic medium every 3 days.
8. Measure ALP activity about 1–2 weeks after MSC osteogenetic culture [29, 30]. 
Aspirate medium and gently wash cells twice with PBS.
9. Add 600 μL of lysis buffer (0.5% Triton-X 100 in molecular grade ddH2O) to 
each well and then scrape the cells off the surface using the end of a pipette tip.
10. Transfer lysates to centrifuge tubes. Prepare 15 mL conical tubes equal to the 
number of tubes maintaining lysates.
11. Dissolve the contents of a 40 mg capsule of phosphatase substrate (Sigma) in 
10 mL ddH2O. Scale up if necessary.
12. Add 500 μL of 1.5 M alkaline buffer solution (Sigma) to each tube. Add 500 μL 
of phosphatase substrate solution into each tube. Keep tubes in 37°C water bath.
13. Vortex samples and add 100 μL of each lysate to 15 mL tubes within 30 sec-
onds. Fifteen minutes after the first sample is added, add 1 mL of 1 N NaOH to 
each tube in 30 second intervals removing tubes from water bath. The reaction 
will take place for 15 minutes at 37°C for each tube.
14. Prepare standard curve (Sigma) (Note: prepare 100 nmol/mL solution of p-
nitrophenol by combining 100 μL of 10 mM p-nitrophenol standard solution 
with 9.9 mL 0.02 N NaOH).
15. Add 300 μL of standards and samples in triplicate to a 96-well plate.
16. Measure the absorbance using excitation filter of 405 nm. One enzyme unit of 
ALP is defined as the quantity of enzyme which produces 1 nmol p-nitrophe-
nol per 15 minutes [29].
3.1.2 Colorimetric quantitative calcium assay
1. Aspirate or pipette out all culture medium from each well of the 6-well culture 
plate that contains induced or control cells to be tested.
Figure 1. 
Osteogenic culture of human BM-MSCs. Representative images (10×) of human BM-MSC osteogenesis on day 
12 (A), day 17 (B), and day 26 during osteogenic culture.
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2. Rinse the cells twice with PBS. Add 200 μL of PBS to the side of each well, not 
to dislodge the cells. Aspirate off the PBS and re-rinse.
3. Add 125 μL of 0.5 N HCl to each well.
4. Scrape the cells off of the surface using a cell scraper and transfer the cells 
and HCl to a 1.5 mL polypropylene microcentrifuge tube with a tight fit-
ting cap.
5. Add an additional 125 μL of 0.5 N HCl to each cell to recover any cells remain-
ing in the well, and transfer this to the appropriate tube.
6. Samples may be capped tightly and stored at −20°C if they are not to be 
tested immediately.
7. Extract the calcium from the cells by shaking the tubes on an orbital shaker for 
4 hours at 4°C. If using frozen samples, allow extra time for samples to thaw.
8. Centrifuge the sample tubes at 500 g for 2 minutes.
9. Carefully collect the supernatant with extracted calcium, without disrupt-
ing the cell pellets, and transfer these to a new tube.
10. Prepare a standard curve with the calcium standard and determine the amount 
of calcium in each control and osteogenesis-induced samples. Follow the in-
structions provided in the Stanbio Total Calcium LiquiColor® Procedure No. 
0150 (Stanbio Laboratory).
11. Three μL of sample vs. 297 μL of assay reagent (1:100 ratio for sample to re-
agent) for 96-well plate is used for each calcium determination. Assay reagent 
is mixed by equal volume of two solutions (Color Reagent and Base Reagent) 
provided in the kit. Distribute the assay reagent by multipipettor after adding 
samples. Absorbance is read at 550 nm.
12. Unused sample extract may be re-frozen for future re-assay. If the reading was 
out of range, the sample can be diluted with ddH2O in a total volume of 3 μL 
(e.g. 1 μL of sample+2 μL of ddH2O) and re-assayed again.
3.1.3  3-D culture of human BM-MSCs and calcium deposition measured by von 
Kossa staining
PuraMatrix™ hydrogel (BD Biosciences) is a 16-amino acid synthetic peptide 
hydrogel composed of a repeating sequence of arginine, alanine, aspartate, and 
alanine (RADA16) [31], which is widely used for 3-D culture.
1. 3-D culture of human BM-MSCs on PuraMatrix hydrogel as follows.
2. The stock of 1% peptide solution can be sonicated for 30 minutes to decrease 
its viscosity and then diluted with sterile ddH2O to a final concentration of 
0.25% (w/v).
3. 300 μL of 0.25% gel solution is loaded into each well of the 24-well plate until 
it is uniformly spread.
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4. The gelation is initiated by slowly dripping the medium along the wall of the 
well. 300 μL of medium is again added carefully on top and the plate is incu-
bated at room temperature for one hour equilibration.
5. After the peptide has assembled into hydrogel, the medium is changed 
two times over one hour to equilibrate the growth environment to physi-
ological pH.
6. The equilibrated samples are stored overnight at 37°C incubator and the cells 
are seeded the next day.
7. Prepare the total of 4 × 104 cells suspended in MSC growth medium and 
4 × 104 cells are seeded onto the hydrogel. The following day (Day 0), the me-
dium will be replaced by osteogenic medium.
8. Von Kossa staining can be conducted at day 24 after differentiation [30]. MSCs 
are rinsed with the Tyrode’s balanced salt solution and fixed with 10% buffered 
formalin (Fisher Scientific) for 30 minutes.
9. Incubated with 2% silver nitrate solution for 10 minutes in the dark.
10. Rinse with ddH2O and expose to light for 15 minutes.
11. Bright-field images of stained samples are captured with an inverted mi-
croscope.
3.1.4  3-D cellular culture conducted by encapsulation of human MSCs in 
PuraMatrix™ hydrogel
1. To generate a 0.25% final concentration of PuraMatrix™ hydrogel for cells 
encapsulation, one part of 1% PuraMatrix™ hydrogel is diluted with same 
volume of sterile 20% sucrose, to reach 0.5% PuraMatrix™ hydrogel in 10% 
sucrose, and then mix with one part of 2× concentration of cells resuspended 
in 10% sucrose.
2. For 24-well plates, 300 μL of PuraMatrix mixture is loaded into each well and 
300 μL of medium is layered on top of the gel. The gelation of the PuraMatrix 
is completed in an incubator for 60 minutes.
3. Change medium the next day.
4. Von Kossa staining can also be conducted, as described above, or collect 
cells as follows for other experiments.
5. Mechanically disrupt BD PureMatrix™ and cells in the well or cell culture 
insert by pipetting the media and gel up and down.
6. Transfer to a 15 mL conical tube.
7. Rinse out the well or cell culture insert using PBS.
8. Centrifuge at 150 × g for 5 minutes. Discard supernatant. The pellet at the bot-
tom of the tube contains cells and BD PuraMatrix fragments.
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9. Resuspend pellet in 2 mL of PBS. Spin and collect pellet again.
10. Resuspend pellet in 1 mL of trypsin–EDTA and incubate at 37°C for 5–10 min-
utes. This will help separate cells that are still attached to each other.
11. Add 5 mL PBS to spin cell pellet again.
12. Aspirate the supernatant (do not disturb the gel). Resuspend pellet again in 
1 mL of trypsin–EDTA and incubate at 37°C for 5–10 minutes.
13. Add 5 mL PBS to spin cell pellet again.
14. Aspirate the supernatant. Carefully take out one third of the gel pellet. Do not 
disturb the bottom (two-third) part of the gel.
15. Wash with PBS twice.
16. Add appropriate amount of lysis buffer to perform cell lysis and collect 
cell sample.
3.2 3-D cell pellet culture and chondrogenesis of human BM-MSCs
Chondrogenic medium: 95% DMEM high-glucose medium (Sigma-Aldrich, St 
Louis, MO), 1% 1 × ITS+1 solution (BD Biosciences, San Jose, CA), 1% Pen-Strep, 
100 μg/mL sodium pyruvate (Invitrogen, Carlsbad, CA), 50 μg/mL AsAP, 40 μg/
mL L-proline (Sigma-Aldrich, St Louis, MO), 0.1 μM dexamethasone, and 10 ng/
mL recombinant human TGF-β3 (Lonza, Walkersville, MD).
Passage 4 human BM-MSCs are used for chondrogenic differentiation. 
Chondrogenic differentiation is induced by chondrogenic medium (Figure 2).
1. In order to form a chondrogenic pellet, approximately 2.5 × 105 human BM-
MSCs are centrifuged down in a 15 mL conical tube at 150 × g for 5 minutes at 
room temperature.
2. Five hundred μL of chondrogenic medium is used to resuspend the 2.5 × 105 
cells to a final concentration of 0.5 × 106 cells/mL.
Figure 2. 
Chondrogenic culture of human BM-MSCs. Representative images (10×) of immunohistochemical staining of 
collage II (A) and aggrecan (B) in pellet culture samples at day 17 during chondrogenesis [29].
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3. Cells are centrifuged down again. Place the 15 mL conical tube in the incubator 
at 37°C with 5% humidified CO2.
4. MSCs are shaped into the pellet after 24 hours incubation without disturbance.
5. The cell pellet is fed every 3 days for about 2–4 weeks and, after that, the chon-
drogenic pellet is harvested and sample processing is described as follows for 
immunohistochemistry analysis (e.g. examination of the expression levels of 
Collagen II, X and Aggrecan) [29, 32].
3.2.1 Sample processing for immunohistochemistry analysis
Day 1: Fixation and dehydration
1. Rinse specimen in PBS.
2. Fix samples for 45 minutes in acid-formalin at 4°C.
3. Rinse specimen in PBS twice.
4. Embed specimen in 2% agarose.
5. Transfer to vial and treat with 50% absolute ethanol for 1 hour at room tem-
perature.
6. Transfer to 70% Absolute ethanol for 1 hour at room temperature.
7. Transfer to 95% Absolute ethanol for 1 hour at room temperature.
8. Repeat the step 7.
9. Transfer to 100% absolute ethanol for 1 hour at room temperature.
10. Leave specimen at 4°C overnight.
Day 2: Clearing and infiltration
1. Transfer to 100% CitriSolv (Fisher Scientific, catlog 22-143-975) for 1 hour at 
room temperature.
2. Transfer to 100% CitriSolv for 1 hour at 55°C.
3. Transfer to 1:1 mixture of CitriSolv/Micro-cut paraffin for 1 hour at 55°C.
4. Repeat the step 3.
5. Transfer to 100% Micro-cut paraffin for 1 hour at 55°C.
6. Repeat the step 5.
Day 3: Embedding
1. Transfer to 100% Micro-cut paraffin for 1–2 hours at 55°C.
13
Isolation and Expansion of Mesenchymal Stem/Stromal Cells, Functional Assays and Long-Term…
DOI: http://dx.doi.org/10.5772/intechopen.100286
2. Position specimen in Peel-Away mold with 100% paraffin.
3. Allow specimen to harden overnight.
4. Specimen may be sectioned the following day.
5. Conduct immunohistochemistry.
3.3 In vitro adipogenesis of human MSCs
Adipogenic medium: DMEM (1 g/L glucose), 10% FBS, 1% penicillin/strep-
tomycin, 10 mg/mL insulin, 1 mM dexamethasone, 0.5 mM methylxanthine, and 
200 mM indomethacin.
Passage 4 human BM-MSCs are used for adipogenic differentiation. Adipogenic 
differentiation is induced by adipogenic medium.
1. Harvest cells from passage 4, as described in the previous section.
2. Resuspend cells in adipogenic medium carefully.
3. Transfer the single cell suspension in triplicate to 6-well plates (1 × 105 cells/well).
4. Culture cells in the incubator at 37°C with 5% humidified CO2 for 3 weeks.
5. Change medium every 2–3 days.
6. After 3 weeks, aspirate adipogenic medium and wash cells twice with PBS.
7. Cells are fixed in ice-cold methanol for 10 minutes.
8. Aspirate methanol completely and wash cells twice with ddH2O.
9. Add Oil Red O staining reagent to the wells to stain lipid vacuoles at room tem-
perature and mix slowly about 20 minutes on a shaker plate.
10. Aspirate Oil Red O staining reagent and wash cells twice with ddH2O.
11. Observe and check the stained cells with phase contrast microscopy.
3.4 CFU-F assay
CFU-F assay can be used in vitro to evaluate the proliferation potential of MSCs. 
CFU-F assay is a well-established method for the quality control of MSCs’ prepara-
tion. This section describes a traditional assay for CFU-F to evaluate the colony 
forming ability of human MSCs.
1. Collect cells from passage 4.
2. Prepare the single cell suspension in growth medium and seed cells in the 
6-well plates in triplicate at three different densities, 1.5 × 105, 2.5 × 105, and 
5 × 105 cells/well, in 2 mL growth medium, respectively.
3. Culture cells in the incubator at 37°C with 5% humidified CO2 for two weeks.
Cell Culture
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4. Change medium twice each week and check with phase contrast microscopy daily 
to prevent overgrowth. Stop cell culture as soon as colonies are forming visibly and 
proceed with the Giemsa staining of CFU-F colonies on a benchtop as follows.
5. Wash the culture dishes twice with PBS.
6. Fix cells by adding 2 mL methanol to each well for 5 minutes at room temperature.
7. Gently remove the methanol and discard into the bio-hazardous waste.
8. Air dry the culture vessels and add the diluted Giemsa staining solution for 
5–10 minute at room temperature.
9. Remove Giemsa staining solution and wash twice with ddH2O.
10. Count visible colonies manually with a diameter greater than 5 mm.
3.5 Co-culture of MSCs with cancer cell line
There are various 2-D or 3-D, dyeing or not dyeing, co-culture models of human 
MSCs and other cell sources to study cell–cell interaction, cell proliferation, MSCs’ 
immunomodulatory capacity, and the cellular contribution of each cell type. These 
methods making co-cultures of MSCs and other cells are well-established, such as 
co-cultures of MSCs and human peripheral blood mononuclear cells [33, 34], MSCs 
and T cells [35], MSCs and human hematopoietic stem cells [36], MSCs and umbili-
cal vein endothelial cells [37]. MSC-cancer cell (PC-9) co-culture will be described 
in this section (Figure 3).
3.5.1  Preparation of MSCs with CellTracker™ Red dye (CellTracker™ CM-DiI, 
C7000)
1. Culture MSCs in an appropriate tissue culture ware (e.g. a 6-well plate)
2. Remove culture medium and wash with PBS twice.
Figure 3. 
Human BM-MSCs-PC-9 co-culture. Representative images ((A) 5×; (B) 20×) of co-cultures of human BM-MSCs 
labeled with CellTracker™ red dye and PC-9 cells transfected with copGFP, nuclei counterstained with DAPI.
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3. Prepare CellTracker™ working solution in MSC growth medium. Make stock 
solution of lipophilic tracers in DMSO at 2 mM. Dilute the stock solution in 
MSC growth medium at 2 μM.
4. Add the working solution in the tissue culture vessel to cover the entire cell surface.
5. Incubate for 5 minutes or less in incubator at 37°C with 5% humidified CO2.
6. Remove the CellTracker™ working solution.
7. Wash with MSC growth medium once.
8. Add MSC growth medium and return the tissue culture vessel to the incubator.
3.5.2 Preparation of PC-9 cells labeling with GFP
1. PC-9 cells labeling with copGFP (Santa Cruz, sc-108083) is performed using the 
lentiviral technique. Lentivirus is produced by using Lipofectamine™ 2000 (In-
vitrogen), according to the manufacturer’s instructions. After transfection, PC-9 
cells expressing copGFP may be isolated via puromycin (2 μg/mL) selection.
2. Continue to serially passage.
3. Collect PC-9 cells for cell co-culture.
3.5.3 MSC-PC-9 cell co-culture
1. Harvest MSCs with CellTrcker™ red dye and wash with PBS once.
2. Prepare the single cell suspension in growth medium at an appropriate cell 
concentration and transfer the cell suspension in a 6-well plate or a special 
chamber.
3. Culture cells in the incubator at 37°C with 5% humidified CO2 for about 
3 hours to allow cells to attach.
4. Change fresh growth medium slowly.
5. Add PC-9 cells in the 6-well plate (the same cell number of MSCs). Gently tap 
the side of the flask.
6. Return the 6-well plate to the incubator and culture cell overnight.
7. Check the cell co-culture under the contrast microscope and image under 
microscopy.
3.6 In vitro migration assay
The intercellular communication can be executed through a direct cell–cell 
interaction or through paracrine signaling mediated by a combination of active 
molecules. The major signaling molecules include cytokines, growth factors, 
chemokines, which can be generated and expressed in a wide variety of cell 
types including tumor cells and MSCs in response to multiple signals such as 
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inflammatory or tumor microenvironment. Circulating MSCs are driven by such 
signaling molecules to home and subsequently migrate into the sites of tissue 
injury or disease. It is critical for the ability of MSCs to migrate and identify the 
injury sites for tissue repair and regeneration. Clinical data are still lacking for 
MSCs’ homing and distribution of transplanted MSCs in the body, albeit a large 
number of in vivo studies are conducted on homing and migration pathways of 
MSCs for targeted stem cell-based therapies.
There are different approaches for improvement of MSC homing and migration. 
In this section, in vitro migration capacity of human BM-MSCs is evaluated by using 
an 8 μm-pore transwell chamber inserts (Corning).
1. Harvest MSCs and prepare cell suspension in the serum-free medium.
2. Transfer the cell suspension to the upper layer of a transwell insert at a den-
sity of 4 × 104 cells/cm2 and allow cells to migrate to the lower compartment 
containing MSC growth medium overnight in the incubator at 37°C with 5% 
humidifies CO2.
3. Cells from the upper chamber of transwell are migrated. Gently scrape the 
MSCs using the cotton swab at the upper layer of the membrane.
4. The migrated MSCs at the lower layer are stained with 0.1% crystal violet.
5. Check the cells and image under a light microscope.
6. Count the number of stained MSCs manually.
4. In vitro long-term culture associated alterations of MSCs
4.1 Morphological and immunophenotypic alterations of MSCs
It is well known that MSCs demonstrate biological alterations in the course of 
in vitro long-term culture. Different tissue derived MSCs may present different 
morphological and immunophenotypic characteristics in the expansion culture. 
At present, there is lack of a unifying definition for the “passage” of MSCs. 
Morphological changes are continuous during the long-term culture and expansion 
of BM-MSCs [38–40], which display a fibroblast-like appearance at early passages 
while the flattened and larger morphology as well as a visible increase of cellular 
granularity in late passages. For example, one previous study showed that human 
BM-MSCs were consistent with a morphological appearance from passage 1 to pas-
sage 6–8 and beyond that period such cells became large and flat [40].
During further cultivation, MSCs demonstrate the altered common immunolog-
ical surface markers. Comparison of the early and late passages of BM-MSCs reveals 
that no differences are observed between passage 2 and 6 MSCs in expression of 
CD44, CD90, CD105, HLA-ABC, and HLA-DR, while CD106 is downregulated in 
MSCs of passage 6 [41]. Research has also reported that the expression pattern of 
the common surface markers maintains consistently with consecutive passaging up 
to passage 8 of BM-MSCs [40]. In contrast, the positive expression of the common 
surface markers such as CD73, CD90 and CD105 presents at the passage 30 of 
human adipose-derived MSCs (AD-MSCs) [42] and human umbilical cord MSCs 
(UC-MSCs) [43].
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4.2 Alterations of proliferation and differentiation of MSCs
MSCs exhibit a high proliferation rare at lower passage and, however, the rapid 
growth kinetics decrease gradually with consecutive cell passaging. A linear cor-
relation is observed between cumulative population doubling and days in culture 
up to passage 6–8 of human BM-MSCs and the passage-dependent decrease in the 
proliferation rate is also observed beyond that period [40]. A reduction in the pro-
liferation in the course of long-term cultivation has been reported in human dental 
pulp tissue-derived MSCs [44] and human tonsil-derived MSCs [45].
The differentiation ability of human BM-MSCs vary in long-term culture mani-
fested by the significant reduction in expression levels of the osteogenic markers, 
such as ALP and osteocalcin, and adipogenic markers, such as fatty acid binding 
protein-4 and lipoprotein lipase at the late passages [45]. It has been reported that 
25% samples of BM-MSCs from different donors in the 8th passage and the 20% in 
the 10th passage lost their osteogenic differentiation potential [46]. Similarly, 10% 
BM-MSC samples in the 6th passage, the 50% in the 8th passage, and the 60% in the 
10th passage also lost their adipogenic differentiation [46]. In contrast, an in vitro 
differentiation study has also reported that the potential of adipogenesis decreases 
in higher passages (from the 5th passage) whereas the propensity for osteogenesis 
increases in the long-term culture [39].
4.3 Replicative senescence during long-term culture expansion of MSCs
Replicative senescence is known as the irreversible growth arrest of the mitotic cells 
and is induced by telomere shortening. The expression of senescence markers such 
as senescence-associated β-galactosidase, heterochromatin protein-1, and p16INK4a 
increase during aging [47, 48]. Molecular damage and epigenetic alterations occur in 
aging stem cells [49], which can result in the impairment of stem cell function.
There are various signaling pathways involved in the senescence of MSCs, 
including oxidative damage [50, 51], age-related defects [52], and senescence 
associated up-regulation of microRNAs [53]. MSC senescence can be observed with 
long-term in vitro cultivation [54, 55], thus suggesting that a certain proportion of 
MSCs may undergo senescence during culture expansion. In vitro long-term culture 
of MSCs can induce continuous changes in gene expression [39, 56]. The expression 
levels of the senescence related genes, such as p16, p21 and p53, increase gradually in 
MSCs in the course of in vitro culture expansion [57]. DNA-methylation changes in 
MSCs during long-term culture have been investigated as an important epigenomic 
feature of replicative senescence of MSCs [58–60]. DNA-methylation changes may 
affect the proliferation and differentiation of MSCs. Differential methylation pat-
terns of gene and miRNAs show between early-passage (passage 5) and late-passage 
(passage 15) MSCs [60]. Some genes that are hypermethylated at passage 5 present 
the lower mRNA expression than does these hypermethylated at passage 15 and vise 
versa [60].
Senescent cells secrete a complex combination of interleukins, chemokines, 
growth factors, proinflammatory/inflammatory cytokines, which compose the 
senescence-associated secretory phenotype (SASP) [61, 62]. One previous report 
has shown that conditioned medium (CM) collected from senescent BM-MSC 
culture at passage 10 is able to trigger senescence in young cells [63]. The key factors 
of senescent MSC CM needed for triggering senescence in the young MSCs have 
been characterized as insulin-like growth factor binding proteins 4 and 7, which 
are linked to cellular senescence and apoptosis [63]. Similarly, monocyte chemoat-
tractant proten-1 (MCP-1), as a dominant component of the SASP, is markedly 
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increased in the conditioned medium of the late-phase MSCs and MCP-1 treatment 
significantly increase the senescence phenotypes of umbilical cord blood-derived 
MSCs via its cognate receptor chemokine receptor 2 signaling cascade [64]. 
Senescence-associated changes are observed in the metabolome of MSCs during 
replicative senescence, including down-regulation of nicotinamide ribonucleotide 
and up-regulation of orotic acid, which may be used to monitor the cellular senes-
cent state during culture expansion of MSCs [65].
4.4 In vitro long-term culture associated spontaneous transformation of MSCs
Sarcoma represents a very heterogeneous group of relatively rare tumors and a 
variety of different studies have investigated to support the MSC origin of sarcoma. 
There are a number of cellular and molecular mechanisms of MSC transforma-
tion for better understanding of MSCs’ contribution to sarcomagenesis [66]. The 
majority of published research articles indicate that various sarcoma types have 
been shown MSCs’ origin. Several group have reported spontaneous transforma-
tion in human and murine MSCs after long term culture [67–70]. For example, one 
study has reported that murine BM-MSCs are spontaneously transformed at passage 
29 under standard conditions and that these transformed MSCs are able to gener-
ate fibrosarcoma in immunocompromised mice [70]. Accumulated chromosomal 
abnormalities, such as chromosome instability, chromosomal imbalances and 
aneuploidy, are suggested to be associated with the transformation of BM MSCs 
[70]. Indeed, chromosomal aberrations (chromosomal level) in in vitro cultures of 
human MSCs have been reported in previous studies, including human BM-MSCs 
after passage 4 [71], human AD-MSCs from passage 5 [72], and UC-MSCs from 
passage 5 [73].
There are also studies that have not detected the transformation of MSCs in 
long-term culture [74–76]. One previous study reports that human BM-MSCs 
do not undergo malignant transformation after long-term in vitro culture for up 
to 44 weeks and these cells maintain a normal karyotype [75]. In agree with the 
previous report [75], another study has described the occurrence of aneuploidy in 
cultivated human MSCs without evidence of transformation either in vitro or in vivo 
[76]. In addition, Røsland G.V. et al have reported that human BM-MSC spontane-
ous transformation phenomenon occurred in consequence of the cross-contamina-
tion between the transformed human MSCs and human cancer cells [77]. To date, 
there is no solid evidence for the transformation of different sarcoma subtypes 
from MSCs and it leaves an uncertainty for MSCs with the ability to spontaneously 
transform.
5. Conclusion and perspective
MSCs provide huge opportunities in translational medicine for treatment of a 
range of diseases or medical conditions. MSCs are multipotent stem cells and such 
cells can be isolated from various tissues including bone marrow, a major source 
of human MSCs. Given that a large number of MSCs are required for the clinical 
application, in vitro expansion of MSCs is critical. However, MSCs at higher passage 
could lead to the culture-associated alterations, such as cellular morphology, immu-
nological surface markers, proliferation, differentiation, and cell genetics. Due to in 
vitro long-term culture associated spontaneous transformation of MSCs, the safety 
of MSC therapy remains the major concerns. Human MSCs from various tissues 
present the varies biological properties. At present, consensus is lacking regarding 
materials and culture protocols, culture conditions, supplement of growth factors, 
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freezing and thawing (e.g. media), and functional assays. Therefore, standardizing 
the procedures for preparation of MSCs would be needed for pre-clinical studies 
and clinical application of MSCs.
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